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E-mail address: smadsen@vetmed.wsu.edu (S.A. MThe protein misfolding cyclic ampliﬁcation (PMCA) assay allows for detection of prion protein misfolding
activity in tissues and ﬂuids from sheep with scrapie where it was previously undetected by conventional
western blot and immunohistochemistry assays. Studies of goats with scrapie have yet to take advantage
of PMCA, which could aid in discerning the risk of transmission between goats and goats to sheep. The
aim of the current study was to adapt PMCA for evaluation of scrapie derived from goats. Diluted brain
homogenate from scrapie-infected goats (i.e., the scrapie seed, PrPSc) was subjected to PMCA using nor-
mal brain homogenate from ovinized transgenic mice (tg338) as the source of normal cellular prion pro-
tein (the substrate, PrPC). The assay end-point was detection of the proteinase K-resistant misfolded prion
protein core (PrPres) by western blot. Protein misfolding activity was consistently observed in caprine
brain homogenate diluted 10,000-fold after 5 PMCA rounds. Epitope mapping by western blot analyses
demonstrated that PrPres post-PMCA was readily detected with an N-terminus anti-PrP monoclonal anti-
body (P4), similar to scrapie inoculum from goats. This was in contrast to limited detection of PrPres with
P4 following mouse bioassay. The inverse was observed with a monoclonal antibody to the C-terminus
(F99/97.6.1). Thus, brain homogenate prepared from uninoculated tg338 served as an appropriate sub-
strate for serial PMCA of PrPSc derived from goats. These observations suggest that concurrent PMCA
and bioassay with tg338 could improve characterization of goat derived scrapie.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Scrapie is a prion disease of sheep and goats that is part of a
larger group of transmissible spongiform encephalopathies includ-
ing bovine spongiform encephalopathy (BSE), chronic wasting
disease in cervids, transmissible mink encephalopathy, and variant
Creutzfeldt–Jakob disease in humans. This neurodegenerative
disorder is characterized by the conversion of normal cellular prion
protein (PrPC) to a misfolded conformation (PrPSc), which includes
a protease resistant core peptide (PrPres) [1,2]. Antemortem diag-
nosis relies on detection of PrPSc in peripheral lymphoid tissues,
e.g. rectoanal mucosa-associated lymphoid tissue [3,4]. Transmis-
sion of scrapie in sheep may occur via exposure to PrPSc that is
present in the placenta [5,6], blood [7,8], and milk [9,10] from in-
fected ewes with similar routes of transmission anticipated forY-NC-ND license. 
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adsen-Bouterse).goats [11,12]. Despite assumed disease transmission through a
variety of biological sources, detection of PrPSc in ﬂuids and some
tissues by conventional western blot and immunohistochemistry
methods can be challenging.
Protein misfolding cyclic ampliﬁcation (PMCA) is an in vitro pro-
cess thought to mimic the in vivo conversion of PrPC to PrPres.
PMCA is generally conducted in repeating cycles of seeded conver-
sion (incubation phase) followed by disaggregation (sonication
phase) [13,14]. Not only has PMCA been utilized to amplify very di-
lute PrPSc seed [15,16], but newly formed PrPSc can be infectious
[16,17] and maintain strain-speciﬁc properties [18]. To date, PMCA
has proven to be a useful tool in detecting PrPSc from several spe-
cies [19–25] including humans [26] and sheep [20,27].
Through PMCA, scrapie associated prion misfolding activity has
been conﬁrmed in tissues from sheep in which PrPSc detection by
conventional immunoassays is limited. Such samples include blood
[27], milk [28], saliva [29], feces [30], and urine [31]. Detection of
PrPSc in goats by conventional immunoassays appears to be, at
least in some tissues, more limited than sheep. However, PMCA,
which could aid in investigating the transmission risk from goat
to goat and goat to sheep, has been minimally applied to caprine
tissues [20]. The amount of available PrPC is a critical factor in
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tration of PrPC expressed in the brain of transgenic mice improves
ampliﬁcation of PrPSc [21,32,33]. Thus, the aim of the current study
was to evaluate PrPSc from goats ampliﬁed by PMCA using normal
brain homogenate from ovinized mice as the source of PrPC and
compare it to misfolded prion generated in vivo by mouse bioassay
using the same ovinized mouse strain.
2. Materials and methods
2.1. Animals, tissue collection, homogenate preparation
All animal handling and tissue collection were performed
according to protocols approved prior to study initiation by the
Washington State University and University of Washington Institu-
tional Animal Care and Use Committees. One Nubian goat (case
number 3953) and two domestic mixed breed goats (3538 and
30-75) were identiﬁed as infected with naturally acquired scrapie.
The Nubian goat and two mixed breed goats were acquired from
different ﬂocks. Postmortem disease conﬁrmation was performed
at the National Veterinary Services Laboratory, USDA, Ames IA,
USA, using immunohistochemistry analysis of brainstem with
monoclonal antibody (mAb) F99/97.6.1. At the time of death, brain
tissue was harvested and stored at 80 C. Homogenates (10% w/v)
were prepared in sterile saline as described [34] and stored at
80 C until bioassay or PMCA. The presence of PrPSc was con-
ﬁrmed by western blot analysis of PrPres.
Brain tissue was also harvested from a scrapie-free Saanen goat
(4111; Washington State University ﬂock) at euthanasia and stored
at 80 C. No PrPSc was detected by immunohistochemistry analy-
ses of brainstem and retropharyngeal lymph node. Medulla and
pons of the hindbrain were homogenized with a disposable tissue
grinder (VWR) in ice–cold conversion buffer [PBS supplemented
with 150 mM NaCl, 4 mM EDTA, 1% Triton X-100, and complete
protease inhibitor (Roche)] to yield a 10% (w/v) normal brain
homogenate (gNBH). Homogenates were centrifuged at 500g for
60 s at 4 C to remove large particulate matter and aliquots stored
at 80 C.
Scrapie-free ovinized mice (strain tg338, [35,36]) provided brain
tissue for PMCA substrate. Breeding pairs of transgenic tg338 mice
were kindly provided by Dr. Hubert Laude (Institut National de la
Recherche Agronomique, France) and held in a breeding colony at
the University of Washington (UW). The presence of the transgene
was conﬁrmed by DNA sequence analysis of tail snips.Whole brains
were harvested at the time of euthanasia and stored at 80 C until
homogenization in conversion buffer as described above to create
10% normal brain homogenate (mNBH) for PMCA.
2.2. Serial protein misfolding cyclic ampliﬁcation
Serial PMCA was performed as previously described [15,27,37]
with the following modiﬁcations. Caprine brain homogenate
(10% = 101) was thawed on ice and diluted 10-fold into conversion
buffer. The resulting 1% homogenate (102) was further diluted 10-
fold into NBH to yield pre-ampliﬁcation dilutions of 103 to 1010 of
which 100 ll each were transferred to 0.2 ml reaction tubes. The
remaining volume of each dilution was stored at 80 C (unampli-
ﬁed control). Reaction tubes were placed in a microplate horn soni-
cator (Misonix S-4000; Qsonica) containing water maintained at
37 C by a recirculating chiller (VWR) and incubated 1 hour prior
to the ﬁrst sonication. Samples underwent cycles of sonication
(ultrasonic amplitude of 75 for 40 s) and incubation (59 min 20 s).
At the end of 48 cycles, deﬁned as one round, samples were diluted
1:3 into fresh NBH before initiating the next round of PMCA;
remaining product was stored at80 C. Up to ﬁve rounds of PMCA
were performed.2.3. Bioassay
Bioassay in transgenic ovinized mice (tg338) was recently de-
scribed by O’Rourke and colleagues [34]. Inoculated animals and
age-matched uninoculated controls were monitored daily for
appearance of clinical signs and culled at terminal disease. Brains
were collected at euthanasia and frozen at 20 C.
2.4. Western blot
Western blot analyses of PMCA products and brain homogenates
from goats or inoculated tg338 mice were performed as described
elsewhere [34] except that all samples were incubated with
200 lg/ml proteinase K (PK) at 37 C for 90 min prior to electropho-
resis. Immunodetection of PrPreswas performedwith either primary
mAb F99/97.6.1 (3.5 lg/ml; VMRD Inc.) or mAb P4 (0.2 lg/ml;
R-Biopharm AG) and HRP-conjugated goat anti-mouse IgG1
(1:5000; Southern Biotechnology) or HRP-conjugated goat anti-
mouse IgG, H + L (1:7000; KPL). The chemiluminescent signal
(Amersham ECL; GE Healthcare) was captured on ﬁlm (Kodak Bio-
Max); digital images were obtained with an Alpha Innotec image
analyzer (Alpha Innotech Corp.).
2.5. Proteinase K and epitope site mapping
Polymerase chain reaction and DNA sequence analysis of
the open reading frame by standardmethodswas used to determine
diploid PRNP genotypes of donor goats [38] and ovinized mice [39].
The open reading frames were translated and aligned using Vector
NTI Advance software (version 11.5.1; Invitrogen). Putative PK
cleavage sites were determined using the online resource ‘‘Peptide
cutter’’ (http://web.expasy.org/peptide_cutter/). The published PrP
epitope sequences recognized by mAbs P4 [40] and F99/97.6.1
[41] were used for alignment.3. Results and discussion
3.1. Serial PMCA of PrPSc from goats
Selection of substrate is an important component in ampliﬁca-
tion of PrPSc by PMCA. Early studies with PMCA utilized brain
homogenate prepared from uninfected individuals of the same
species as the misfolded seed [20]. Thus, our initial PMCA reactions
utilized homogenate prepared from medulla and hindbrain of an
uninfected goat (gNBH). Interestingly, this substrate did not sup-
port protein misfolding regardless of various combinations of son-
ication time/power, incubation, and number of cycles per round
(data not shown). Recent reports demonstrated that ovinized
transgenic mice, tg338, can be a source of substrate for PMCA anal-
yses of ovine scrapie [32,33] and tg338 has also been successfully
used for bioassay of caprine scrapie [34]. Thus, we selected brain
from healthy, uninoculated tg338 to serve as PMCA substrate.
Tg338 brain homogenate (mNBH) prepared in PMCA conversion
buffer supported misfolding of PrPSc from diluted caprine brain
(Fig. 1). A 100-fold or greater dilution of 10% caprine brain homog-
enate resulted in weak to no western blot detection in samples
pre-PMCA. After one PMCA round, the pre-PMCA dilution of 103
was more readily detected by western blot with the signal becom-
ing stronger after each additional round. Pre-PMCA dilutions of
104 and 105 were consistently detected by rounds 3 and 5,
respectively, in all samples tested. Reactions were terminated at
round 5 as a low level of spontaneous misfolding was detected in
the negative control (103 gNBH in mNBH).
Several factors may have contributed to this. First, PrPC concen-
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Fig. 1. Ampliﬁcation of PrPSc from caprine brain by serial PMCA with uninfected
tg338 mouse brain as substrate. Caprine brain homogenate (550 lg starting wet
weight; 10% = 101, represented as 1) was serially diluted into mNBH (102–
1010; represented as 2 to 10) and subjected to ﬁve PMCA rounds of 48 cycles of
sonication and incubation. Samples were diluted 1:3 into fresh mNBH between
rounds. Brain from an uninfected goat (gNBH) was diluted to 103 in mNBH as a
PMCA negative control. Pre- and post-PMCA samples underwent PK digestion
(200 lg/ml for 90 min at 37 C) prior to western blot analysis with mAb P4. Shown
are representative blots from one of three goats tested (animal 3953). Molecular
mass markers are indicated on the left.
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Fig. 2. Variable immunodetection of caprine brain homogenate, serial PMCA, and
bioassay products with monoclonal antibodies directed to N-terminal and
C-terminal epitopes of PrP. Representative western blots are shown for 3953
scrapie seed/inoculum (G), PMCA product (P), and bioassay products (B1 = passage
1, B2 = passage 2) after PK digestion (200 lg/ml for 90 minutes at 37 C). In panel A,
all samples were loaded on the same gel for electrophoresis and transfer to PVDF.
Prior to immunodetection with mAb F99/97.6.1 (C-terminus) or mAb P4 (N-
terminus), the membrane was cut (vertical dashed line). In panel B, loading was
adjusted for optimal visualization with respective monoclonal antibodies; samples
were run on two separate gels. M = molecular mass marker; E = empty lane; tissue
equivalents in lg are listed at the base of each lane except for P where 1X = 1 ll
PMCA product after PK digestion.
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ther, whole mouse brains were used to prepare mNBH whereas
caprine medulla and hindbrain were selected for preparation of
gNBH as this is a major site of PrPSc accumulation in classical ovine
and caprine scrapie [42]. It is possible that factors present in other
parts of the brain that were present in the mNBH preparation inﬂu-
enced misfolding. Finally, an additional factor that may have con-
tributed to a lack of detectable ampliﬁcation with gNBH may be
the PRNP genotype of the donor tissue. Evidence suggests that in
sheep the genotype of the substrate donor contributes to PMCA
efﬁciency [27]. In this study, mismatches in the PRNP open reading
frame between the normal brain homogenates from goat 4111 or
tg338 mice and the tissues from infected goats (3953, 3538, and
30-75) were observed at translated codons 127 and 240 (Supple-
mentary Fig. S2). While it is possible that this may have compro-
mised misfolding by PMCA with gNBH, it is not likely as we
observed ampliﬁed misfolding with all three scrapie seeds with
mNBH despite variation between seed and substrate. We also com-
pared translated amino acid sequences of the goats with scrapie to
mNBH at codons 136, 154, and 171 as these sites putatively impact
PMCA when assessing ovine scrapie [27,43]. The tg338 mouse is
homozygous for valine at codon 136, arginine (R) at codon 154,
and glutamine (Q) at codon 171; all goats used in this study are
homozygous for alanine at codon 136 (136AA), 154RR, 171QQ. Un-
like previous observations [27], the difference at codon 136 be-
tween the PMCA seed and substrate did not appear inhibit
ampliﬁcation of PrPSc. Together, our observations suggest that
overexpression of PrPC with the highly convertible 136 V allele in
tg338 brain yields a more efﬁcient substrate than caprine brain
for PMCA of goat derived scrapie.
3.2. Differential immunoreactivity following PMCA versus bioassay
Given the successful ampliﬁcation of goat-derived PrPSc by
serial PMCA when using mNBH and our previous success intransmitting scrapie infection in tg338 mouse bioassay [34], we
examined possible variations in immunoreactivity of misfolded
prion ampliﬁed by serial PMCA versus that accumulating during
bioassay. First, protein loading within sample type was maintained
and immunodetection performed using monoclonal antibodies to
epitopes located in the N- and C-terminus of the full-length prion
protein. Analysis using the N-terminal mAb P4 demonstrated
strong PrPres labeling in the seed/inoculum and PMCA product
but limited labeling of PrPres from mouse brain post-primary
passage bioassay (Fig. 2A). This was consistent with a previous
observation by O’Rourke and colleagues [34]. In contrast, analysis
using the C-terminal mAb F99/97.6.1 demonstrated relatively
weak labeling of PrPres in the seed/inoculum and PMCA product
but strong labeling post-bioassay, i.e., the reciprocal result as com-
pared to mAb P4 labeling. Next, western blots were prepared by
adjusting sample loading to enhance PrPres visualization with each
monoclonal antibody (Fig. 2B). In order to more adequately visual-
ize PrPSc with F99/97.6.1, approximately two times more seed/
inoculum and PMCA product were loaded per lane. This is in con-
trast to less than half as much sample needed for detection with
F99/97.6.1 after mouse bioassay when compared to the amount
loaded for P4 detection. Thus, availability of P4 and F99/97.6.1 epi-
topes varied following in vitro versus in vivo protein misfolding.
The strong signal with mAb P4 in caprine brain homogenate and
post-PMCA versus the weak signal post-bioassay and the reciprocal
response with F99/97.6.1 were unexpected in light of previous
observations of PrPSc from scrapie-infected goats passaged in
tg338 [34]. In that study, the electrophoretic proﬁle of PrPres
differed from the predominant proﬁle observed in a sample of nat-
urally infected goats and was hypothesized to result from a loss of
the P4 epitope. The detection with P4 following primary passage
shown here is more similar to observations of primary passage of
classical ovine scrapie in tg338 [44] whereas the further reduction
of signal upon secondary passage agrees with P4 epitope loss upon
sub-passage of goat-derived scrapie isolates in tg338 [34].
P4 99/97.6.1
* * * 
Fig. 3. Proteinase K cleavage sites and monoclonal antibody epitopes on PrPC expressed in ovinized mouse. Positions of the putative PK cleavage sites (vertical lines) and anti-
PrP epitopes (solid rectangles) recognized by mAbs P4 and F99/97.6.1 along the mature peptide (solid arrow) of ovine PrP as expressed in tg338 mice. Putative cleavage sites
immediately N- and C-terminal to P4 indicated by .
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in vitro (PMCA) and in vivo (bioassay) suggests the presence of
two PK-resistant species that are of similar molecular mass in
the original tissue preparation from the goats utilized in this study.
We hypothesize that one species is preferentially misfolded by
PMCA and maintains the P4 epitope. The other species is preferen-
tially misfolded by bioassay and is readily detected by F99/97.6.1.
It is possible that reduction of the P4 epitope between inoculum,
primary, and secondary passage results from biologic adaptation
of goat derived scrapie to the mouse host despite sole expression
of the ovine PRNP transgene. As illustrated in Fig. 3, there are puta-
tive PK sites located on either side of the P4 epitope of mature
ovine PrP. Promiscuity at the PK site N-terminal (indicated by )
to the P4 epitope resulting in partial removal of the epitope
sequence or complete loss due to cleavage at the site directly
C-terminal (stacked ) to the P4 epitope may contribute to signal
variation as the resulting mixture of PrPSc would include proteins
with the complete and incomplete or missing epitope sequences.
It is also possible that variation in detection of PrPSc with the P4
antibody could be a result of multiple strains more readily distin-
guished upon serial passage in tg338mice [45] but no indication of
multiple strains was suggested for these inocula in observations by
O’Rourke and colleagues [34]. In contrast to our hypothesis of two
highly similar species present in the inoculum is that there is a sin-
gle PK-resistant species that responds differently to in vitro and
in vivo misfolding methods resulting in PK cleavage sites near the
C-terminus more readily available post-PMCA whereas cleavage
sites in the N-terminus are more readily available post-bioassay.
Biological factors that are present and active in vivo (e.g. proteases)
putatively inﬂuence folding. While these may be present in the
brain homogenate used as substrate, they are potentially inactive
due to chemicals included in the conversion buffer (protease inhib-
itors, EDTA, and triton X-100) allowing for alternative misfolding
following PMCA versus that observed post-bioassay. Additional
studies are needed to examine these possibilities.
3.3. Summary
The transgenic ovinized mouse, tg338, is a valuable tool for bio-
assay and PMCA analyses of ovine scrapie in regards to strain char-
acterization [44–46] and assessment of protein misfolding activity
in tissues and ﬂuids that do not demonstrate detectable PrPSc by
conventional immunoassay [32,33]. This study provides the ﬁrst
description of tg338 brain as substrate for in vitro studies of protein
misfolding of goat derived scrapie by serial PMCA, extending our
previous observation that tg338 is a valuable tool for analysis of
caprine scrapie by bioassay [34]. In addition, it appears that meth-
odology (in vitro versus in vivo misfolding) may impact character-
ization when molecular characteristics, such as epitope mapping,
are critical to deﬁning scrapie strains. Assessment of scrapie from
goats by serial PMCA using tg338 mNBH may provide beneﬁts to
traditional mouse bioassay in that results are more rapidly
achieved and putatively yield PrPSc with qualities associated with
the P4 epitope more similar to that occurring in the natural host.Studies of mouse-adapted and human strains of prion disease have
demonstrated that strain characteristics such as electrophoretic
mobility, glycoform analysis, and PK sensitivity are maintained
by PMCA [18]. Future studies will begin to address if concurrent
PMCA and bioassay with tg338 improves characterization of
caprine, and possibly ovine, scrapie strains. In addition, the meth-
odologies described here-in will be adapted for the assessment of
other caprine tissues and ﬂuids as potential sources of scrapie
transmission to goats and sheep.
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